Related Experiment Videos
Normal response to anti-HBV vaccination in children with chronic renal insufficiency
A La Manna1, C Polito, A C Foglia
1Department of Pediatrics, 1st Faculty of Medicine and Surgery, University of Naples, Italy.
Insights
Children with chronic renal insufficiency responded well to anti-hepatitis B virus (HBV) vaccination, similar to healthy controls. Vaccination is recommended before end-stage renal disease in high HBV prevalence areas.
Area of Science:
- Pediatrics
- Nephrology
- Immunology
Background:
- Chronic renal insufficiency (CRI) can impair immune responses.
- Hepatitis B virus (HBV) infection is a significant risk for patients with kidney disease.
- Vaccination is crucial for preventing HBV infection.
Purpose of the Study:
- To evaluate the efficacy of anti-HBV vaccination in children with CRI.
- To compare vaccination response rates between children with CRI and healthy controls.
Main Methods:
- A cohort of 17 children with CRI on conservative treatment received anti-HBV vaccination.
- A control group of 29 healthy children also received the vaccination.
- Immune response was assessed by measuring the percentage of responders and the titre of antibodies against the hepatitis B surface antigen (HBsAb).
Main Results:
- Satisfactory immune responses were observed in both the CRI group and the control group.
- No statistically significant difference was found in the percentage of responders between the two groups.
- Antibody titres (HBsAb) were comparable between vaccinated children with CRI and healthy controls.
Conclusions:
- Anti-HBV vaccination is effective and safe in children with chronic renal insufficiency.
- Vaccination should be administered to children with CRI prior to the development of end-stage renal disease.
- This strategy is particularly important in regions with a high prevalence of HBV infection.
Abstract:
Anti-HBV vaccination was performed in 17 children with chronic renal insufficiency on conservative treatment and in 29 control children. The response to vaccination was satisfactory in patients as well as in the control group and no significant difference was found between the two groups as to percentage of responders and to the titre of HBsAb produced. It appears reasonable to vaccinate all patients with chronic renal insufficiency before they reach end-stage renal disease in areas with high prevalence of HBV infection.